<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0401210378
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Zorta
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ARIPIPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        248.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="UNITED PHARMACEUTICAL COMPANY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            UNITED PHARMACEUTICAL COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AX12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ZORTA &nbsp;contains the active substance aripiprazole and belong to a group of medicines called</p><p>antipsychotics. It is used to treat adults and adolescents aged 15 years and older who suffer from a</p><p>disease characterized by symptoms such as hearing, seeing or sensing things which are not there,</p><p>suspiciousness, mistaken beliefs, incoherent speech and behavior and emotional flatness. People with</p><p>this condition may also feel depressed, guilty, anxious or tense.</p><p>ZORTA &nbsp;is used to treat adults and adolescents aged 13 years and older who suffer from a condition</p><p>with symptoms such as feeling &quot;high&quot;, having excessive amounts of energy, needing much less sleep</p><p>than usual, talking very quickly with racing ideas and sometimes severe irritability. In adults it also</p><p>prevents this condition from returning in patients who have responded to the treatment with ZORTA .</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take ZORTA </strong></p><p>&bull; if you are allergic to aripiprazole or any of the other ingredients of this medicine (listed in</p><p>section 6.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before taking ZORTA .</p><p>Suicidal thoughts and behaviors have been reported during aripiprazole treatment. Tell your doctor</p><p>immediately if you are having any thoughts or feelings about hurting yourself.</p><p>Before treatment with ZORTA , tell your doctor if you suffer from</p><p>&bull; High blood sugar (characterized by symptoms such as excessive thirst, passing of large amounts</p><p>of urine, increase in appetite and feeling weak) or family history of diabetes</p><p>&bull; Fits (seizures) since your doctor may want to monitor you more closely</p><p>&bull; Involuntary, irregular muscle movements, especially in the face</p><p>&bull; Cardiovascular diseases (diseases of the heart and circulation), family history of cardiovascular</p><p>disease, stroke or &quot;mini&quot; stroke, abnormal blood pressure</p><p>&bull; Blood clots, or family history of blood clots, as antipsychotics have been associated with</p><p>formation of blood clots</p><p>&bull; Past experience with excessive gambling</p><p>If you notice you are gaining weight, develop unusual movements, experience somnolence that</p><p>interferes with normal daily activities, any difficulty in swallowing or allergic symptoms, please tell</p><p>your doctor.</p><p>If you are an elderly patient suffering from dementia (loss of memory and other mental abilities), you</p><p>or your career/relative should tell your doctor if you have ever had a stroke or &quot;mini&quot; stroke.</p><p>Tell your doctor immediately if you are having any thoughts or feelings about hurting yourself.</p><p>Suicidal thoughts and behaviors have been reported during aripiprazole treatment.</p><p>Tell your doctor immediately if you suffer from muscle stiffness or inflexibility with high fever,</p><p>sweating, altered mental status, or very rapid or irregular heartbeat.</p><p>Tell your doctor if you or your family/carer notices that you are developing urges or cravings to</p><p>behave in ways that are unusual for you and you cannot resist the impulse, drive or temptation to carry</p><p>out certain activities that could harm yourself or others. These are called impulse control disorders and</p><p>can include behaviors such as addictive gambling, excessive eating or spending, an abnormally high</p><p>sex drive or preoccupation with an increase in sexual thoughts or feelings.</p><p>Your doctor may need to adjust or stop your dose.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>Do not use this medicine in children and adolescents under 13 years of age. It is not known if it is safe</p><p>and effective in these patients.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and ZORTA </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other</p><p>medicines, including medicines obtained without a prescription.</p><p>Blood pressure-lowering medicines: ZORTA &nbsp;may increase the effect of medicines used to lower the</p><p>blood pressure. Be sure to tell your doctor if you take a medicine to keep your blood pressure under</p><p>control.</p><p>Taking ZORTA &nbsp;with some medicines may mean the doctor will need to change your dose of</p><p>ZORTA &nbsp;or the other medicines. It is especially important to mention the following to your doctor:</p><p>&bull; Medicines to correct heart rhythm (such as quinidine, amiodarone, flecainide)</p><p>&bull; Antidepressants or herbal remedy used to treat depression and anxiety <em>(</em>such as fluoxetine,</p><p>paroxetine, venlafaxine, St. John&#39;s Wort)</p><p>&bull; Antifungal medicines (such as ketoconazole, itraconazole)</p><p>&bull; Certain medicines to treat HIV infection (such as efavirenz, nevirapine, an protease inhibitors</p><p>e.g. indinavir, ritonavir)</p><p>&bull; Anticonvulsants used to treat epilepsy (such as carbamazepine, phenytoin, phenobarbital)</p><p>&bull; Certain antibiotics used to treat tuberculosis (rifabutin, rifampicin)</p><p>These medicines may increase the risk of side effects or reduce the effect of ZORTA ; if you get any</p><p>unusual symptom taking any of these medicines together with ZORTA &nbsp;you should see your doctor.</p><p>Medicines that increase the level of serotonin are typically used in conditions including depression,</p><p>generalized anxiety disorder, obsessive-compulsive disorder (OCD) and social phobia as well as</p><p>migraine and pain:</p><p>&bull; Triptans, tramadol and tryptophan used for conditions including depression, generalised anxiety</p><p>disorder, obsessive compulsive disorder (OCD) and social phobia as well as migraine and pain</p><p>&bull; SSRI s (such as paroxetine and fluoxetine) used for depression, OCD, panic and anxiety</p><p>&bull; Other anti-depressants (such as venlafaxine and tryptophan) used in major depression</p><p>&bull; Tricyclic&rsquo;s (such as clomipramine and amitriptyline) used for depressive illness</p><p>&bull; St John&rsquo;s Wort used as a herbal remedy for mild depression</p><p>&bull; Pain killers (such as tramadol and pethidine) used for pain relief</p><p>&bull; Triptans (such as sumatriptan and zolmitripitan) used for treating migraine</p><p>These medicines may increase the risk of side effects; if you get any unusual symptom taking any of</p><p>these medicines together with ZORTA , you should see your doctor.</p><p><strong>&nbsp;</strong></p><p><strong>ZORTA &nbsp;with food, drink and alcohol</strong></p><p>This medicine can be taken regardless of meals.</p><p>Alcohol should be avoided.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask</p><p>your doctor for advice before taking this medicine.</p><p>The following symptoms may occur in newborn babies, of mothers that have used ZORTA &nbsp;in the last</p><p>trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness,</p><p>agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms</p><p>you may need to contact your doctor.</p><p>If you are taking ZORTA , your doctor will discuss with you whether you should breast-feed</p><p>considering the benefit to you of your therapy and the benefit to your baby of breast-feeding. You</p><p>should not do both. Talk to your doctor about the best way to feed your baby if you are taking this</p><p>medicine.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>Dizziness and vision problems may occur during treatment with this medicine (see section 4).</p><p>This should be considered in cases where full alertness is required, e.g. when driving a car or handling</p><p>machines.</p><p><strong>&nbsp;</strong></p><p><strong>ZORTA &nbsp;contains lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor</p><p>before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor</p><p>or pharmacist if you are not sure.</p><p><strong>&nbsp;</strong></p><p><strong>The recommended dose for adults is 15 mg once a day. </strong>However your doctor may prescribe a lower</p><p>or higher dose to a maximum of 30 mg once a day.</p><p><strong>&nbsp;</strong></p><p><strong>Use in children and adolescents</strong></p><p>This medicinal product may be started at a low dose with the oral solution (liquid) form.</p><p>The dose may be gradually increased to <strong>the recommended dose for adolescents of 10 mg once a</strong></p><p><strong>day</strong>. However your doctor may prescribe a lower or higher dose to a maximum of 30 mg once a day.</p><p>If you have the impression that the effect of ZORTA &nbsp;is too strong or too weak, talk to your doctor or</p><p>pharmacist.</p><p><strong>Try to take ZORTA &nbsp;at the same time each day. </strong>It does not matter whether you take it with or</p><p>without food. Always take the tablet with water and swallow it whole.</p><p><strong>Even if you feel better, </strong>do not alter or discontinue the daily dose of ZORTA &nbsp;without first consulting</p><p>your doctor.</p><p>&nbsp;</p><p><strong>If you take more ZORTA &nbsp;than you should</strong></p><p>If you realise you have taken more ZORTA &nbsp;than your doctor has recommended (or if someone else</p><p>has taken some of your ZORTA ), contact your doctor right away. If you cannot reach your doctor, go</p><p>to the nearest hospital and take the pack with you.</p><p>Patients who have taken too much aripiprazole have experienced the following symptoms:</p><p>&bull; Rapid heartbeat, agitation/aggressiveness, problems with speech.</p><p>&bull; Unusual movements (especially of the face or tongue) and reduced level of consciousness.</p><p>Other symptoms may include:</p><p>&bull; Acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating,</p><p>&bull; Muscle stiffness, and drowsiness or sleepiness, slower breathing, choking, high or low blood</p><p>pressure, abnormal rhythms of the heart.</p><p>Contact your doctor or hospital immediately if you experience any of the above.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take ZORTA </strong></p><p>If you miss a dose, take the missed dose as soon as you remember but do not take two doses in one day.</p><p><strong>&nbsp;</strong></p><p><strong>If you stop taking ZORTA </strong></p><p>Do not stop your treatment just because you feel better. It is important that you carry on taking</p><p>ZORTA &nbsp;for as long as your doctor has told you to.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Common side effects (may affect up to 1 in 10 people):</p><p>&bull; Diabetes mellitus,</p><p>&bull; Difficulty sleeping,</p><p>&bull; Feeling anxious,</p><p>&bull; Feeling restless and unable to keep still, difficulty sitting still,</p><p>&bull; Uncontrollable twitching, jerking or writhing movements, restless legs,</p><p>&bull; Trembling,</p><p>&bull; Headache,</p><p>&bull; Tiredness,</p><p>&bull; Sleepiness,</p><p>&bull; Light-headedness,</p><p>&bull; Shaking and blurred vision,</p><p>&bull; Decreased number of or difficulty making bowel movements,</p><p>&bull; Indigestion,</p><p>&bull; Feeling sick,</p><p>&bull; More saliva in mouth than normal,</p><p>&bull; Vomiting,</p><p>&bull; Feeling tired.</p><p>Uncommon side effects (may affect up to 1 in 100 people):</p><p>&bull; Increased blood levels of the hormone prolactin,</p><p>&bull; Too much sugar in the blood,</p><p>&bull; Depression,</p><p>&bull; Altered or increased sexual interest,</p><p>&bull; Uncontrollable movements of mouth, tongue and limbs (tardive dyskinesia),</p><p>&bull; Muscle disorder causing twisting movements (dystonia),</p><p>&bull; Double vision,</p><p>&bull; Fast heartbeat,</p><p>&bull; A fall in blood pressure on standing up which causes dizziness, light-headedness or fainting,</p><p>&bull; Hiccups.</p><p>The following side effects have been reported since the marketing of oral aripiprazole but the</p><p>frequency for them to occur is not known:</p><p>&bull; Low levels of white blood cells,</p><p>&bull; Low levels of blood platelets,</p><p>&bull; Allergic reaction (e.g. swelling in the mouth, tongue, face and throat, itching, hives),</p><p>&bull; Onset or worsening of diabetes, ketoacidosis (ketones in the blood and urine) or coma,</p><p>&bull; High blood sugar,</p><p>&bull; Not enough sodium in the blood,</p><p>&bull; Loss of appetite (anorexia),</p><p>&bull; Weight loss,</p><p>&bull; Weight gain,</p><p>&bull; Thoughts of suicide, suicide attempt and suicide,</p><p>&bull; Feeling aggressive,</p><p>&bull; Agitation,</p><p>&bull; Nervousness,</p><p>&bull; Combination of fever, muscle stiffness, faster breathing, sweating, reduced consciousness and</p><p>sudden changes in blood pressure and heart rate, fainting (neuroleptic malignant syndrome),</p><p>&bull; Seizure,</p><p>&bull; Serotonin syndrome (a reaction which may cause feelings of great happiness, drowsiness,</p><p>clumsiness, restlessness, feeling of being drunk, fever, sweating or rigid muscles),</p><p>&bull; Speech disorder,</p><p>&bull; Sudden unexplained death,</p><p>&bull; Life-threatening irregular heartbeat,</p><p>&bull; Heart attack,</p><p>&bull; Slower heartbeat,</p><p>&bull; Blood clots in the veins especially in the legs (symptoms include swelling, pain and redness in</p><p>the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in</p><p>breathing (if you notice any of these symptoms, seek medical advice immediately),</p><p>&bull; High blood pressure,</p><p>&bull; Fainting,</p><p>&bull; Accidental inhalation of food with risk of pneumonia (lung infection),</p><p>&bull; Spasm of the muscles around the voice box,</p><p>&bull; Inflammation of the pancreas,</p><p>&bull; Difficulty swallowing,</p><p>&bull; Diarrhea,</p><p>&bull; Abdominal discomfort,</p><p>&bull; Stomach discomfort,</p><p>&bull; Liver failure,</p><p>&bull; Inflammation of the liver,</p><p>&bull; Yellowing of the skin and white part of eyes,</p><p>&bull; Reports of abnormal liver tests values,</p><p>&bull; Skin rash,</p><p>&bull; Sensitivity to light,</p><p>&bull; Baldness,</p><p>&bull; Excessive sweating,</p><p>&bull; Abnormal muscle breakdown which can lead to kidney problems,</p><p>&bull; Muscle pain,</p><p>&bull; Stiffness,</p><p>&bull; Involuntary loss of urine (incontinence),</p><p>&bull; Difficulty in passing urine,</p><p>&bull; Withdrawal symptoms in newborn babies in case of exposure during pregnancy,</p><p>&bull; Prolonged and/or painful erection,</p><p>&bull; Difficulty controlling core body temperature or overheating,</p><p>&bull; Chest pain,</p><p>&bull; Swelling of hands, ankles or feet,</p><p>&bull; In blood tests: increased or fluctuating blood sugar, increased glycosylated haemoglobin.</p><p>&bull; Inability to resist the impulse, drive or temptation to perform an action that could be harmful to</p><p>you or others, which may include:</p><p>- Strong impulse to gamble excessively despite serious personal or family consequences</p><p>- Altered or increased sexual interest and behaviour of significant concern to you or to</p><p>others, for example, an increased sexual drive</p><p>- Uncontrollable excessive shopping</p><p>- Binge eating (eating large amounts of food in a short time period) or compulsive eating</p><p>(eating more food than normal and more than is needed to satisfy your hunger)</p><p>- A tendency to wander away.</p><p>Tell your doctor if you experience any of these behaviours; he/she will discuss ways of</p><p>managing or reducing the symptoms.</p><p>In elderly patients with dementia, more fatal cases have been reported while taking aripiprazole. In</p><p>addition, cases of stroke or &quot;mini&quot; stroke have been reported.</p><p><strong>&nbsp;</strong></p><p><strong>Additional side effects in children and adolescents</strong></p><p>Adolescents aged 13 years and older experienced side effects that were similar in frequency and type</p><p>to those in adults except that sleepiness, uncontrollable twitching or jerking movements, restlessness,</p><p>and tiredness were very common (greater than 1 in 10 patients) and upper abdominal pain, dry mouth,</p><p>increased heart rate, weight gain, increased appetite, muscle twitching, uncontrolled movements of the</p><p>limbs, and feeling dizzy, especially when getting up from a lying or sitting position, were common</p><p>(greater than 1 in 100 patients).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the blister and on the carton after</p><p>EXP. The expiry date refers to the last day of that month.</p><p>Do not store above 30C, Use within 6 months after first opening.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to</p><p>throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance is aripiprazole.</p><p><strong>ZORTA &nbsp;</strong><strong>10 mg </strong>tablet contains 10 mg of aripiprazole.</p><p><strong>ZORTA &nbsp;</strong><strong>15 mg </strong>tablet contains 10 mg of aripiprazole.</p><p>&bull; The other ingredients are lactose monohydrate, Corn Starch, microcrystalline cellulose,</p><p>Ferric oxide red (<strong>ZORTA &nbsp;</strong><strong>10 mg)</strong>, Ferric oxide Yellow (<strong>ZORTA &nbsp;</strong><strong>15 mg ), </strong>Hydroxy Propyl Cellulose, Purified water and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                ZORTA  10 mg tablets
Pink, oval scored convex tablets embossed with “N50” on one side and plain on other side.
ZORTA  15 mg tablets
Yellow, round convex tablets embossed with “T22” on one side and plain on other side.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi,</p><p>Riyadh, Kingdome Saudi Arabia.</p><p>info-ksa@mspharma.com</p><p>&nbsp;</p><p><strong>Manufacturer by:</strong></p><p>&nbsp;United Pharmaceutical Mfg. Co. Ltd.- Jordan for MS Pharma-Saudi.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Dec-2020
SPM190361

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي زورتا على المادة الفعالة أريبيبرازول، والتي تنتمي إلى مجموعة من الأدوية تُسمّى مضادات الذهان. يستخدم الدواء لعلاج البالغين والمراهقين الذين يبلغون من العمر 15 عاما فما فوق ويعانون من مرض يتصف بالأعراض الآتية: رؤية وسماع والشعور بأشياء لا وجود لها،</p><p dir="RTL">مع الارتياب والقناعات الخاطئة والكلام غير المتسق واللامبالاة في المشاعر والسلوك. قد يشعر المرضى المصابين بهذا المرض بالاكتئاب والشعور بالذنب والتوتر أو القلق.</p><p dir="RTL">يستخدم <strong>زورتا</strong> لعلاج البالغين والمراهقين الذين يبلغون من العمر 13 عاما فما فوق ويعانون من أعراض معينة مثل: الشعور بالنشاط وامتلاك كميات هائلة من الطاقة والاحتياج القليل للنوم بشكل أقل من المعتاد، والتحدث بطريقة سريعة جدا مع تزايد الأفكار وفي بعض الأحيان قد يُصاب بالانفعال الشديد. يُستخدم الدواء أيضا في البالغين لمنع مثل هذه الأعراض من التكرار في المرضى الذين قد استجابوا من قبل للعلاج بهذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول زورتا في الحالات الآتية:</strong></p><p dir="RTL">&bull; إذا كانت لديك حساسية مفرطة لمادة أريبيبرازول أو لأي مكونات أخرى في هذا الدواء (من المكونات المذكورة في الفقرة 6).</p><p>&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات:</strong></p><p dir="RTL">استشر طبيبك قبل تناول هذا الدواء.</p><p dir="RTL">تم الإبلاغ عن وجود سلوك وأفكار انتحارية أثناء تناول هذا الدواء. يجب إبلاغ الطبيب على الفور إذا كانت تراودك أية أفكار أو شعور تتعلق بأذية نفسك.</p><p dir="RTL">يجب إبلاغ الطبيب قبل البدء في تناول زورتا إذا كنت تعاني من:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى السكر في الدم (الأعراض المصاحبة لذلك: العطش الشديد، التبول بكميات كبيرة، زيادة الشهية والشعور بالضعف) أو وجود تاريخ مرضي عائلي للإصابة بمرض السكر من النوع الثاني.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات صرعية (تشنجات)، حيث أن ذلك يستدعي متابعة الطبيب بشكل مكثف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات غير منتظمة لا إرادية خاصة في عضلات الوجه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل قلبية وعائية (أمراض في القلب والدورة الدموية)، تاريخ مرضي عائلي للإصابة بأمراض القلب والأوعية الدموية، سكتة دماغية أو جلطة دماغية صغيرة، ارتفاع غير طبيعي في ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات الدم، أو وجود تاريخ مرضي عائلي للإصابة بجلطات الدم، وذلك بسبب وجود صلة بين مُضادات الذهان وتكون الجلطات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق وعانيت من فرط المُقامرة.</p><p dir="RTL"><strong>يجب إخبار الطبيب إذا لاحظت الآتي: </strong></p><p dir="RTL">زيادة في الوزن، وجود حركات غير طبيعية، الشعور بالنعاس الذي يعيق القيام بالأنشطة اليومية الطبيعية، وجود أي صعوبة في البلع أو ظهور أعراض الحساسية من الدواء.</p><p dir="RTL">إذا كنت مريضًا من كبار السن وتعاني من فقدان الذاكرة (الخرف وفقدان بعض القدرات العقلية) فيجب على أحد أقاربك أو القائمين على رعايتك إبلاغ الطبيب على الفور إذا سبق لك الإصابة بسكتة دماغية أو جلطة دماغية صغيرة.</p><p dir="RTL">يجب إبلاغ الطبيب على الفور إذا كان يراودك أية أفكار أو شعور يتعلق بأذية نفسك.</p><p dir="RTL">تم الإبلاغ عن وجود سلوك وأفكار انتحارية أثناء العلاج بمادة أريبيبرازول.</p><p dir="RTL">يجب إبلاغ الطبيب على الفور إذا كنت تعاني من تيبس في العضلات أو فقدان مرونة العضلات مع ارتفاع في درجة الحرارة، تعرق، تغير في الحالة العقلية، زيادة كبيرة أو عدم انتظام في سرعة ضربات القلب.</p><p dir="RTL">يجب إبلاغ الطبيب إذا كنت تلاحظ أنت أو أحد أفراد عائلتك أو القائمين على رعايتك ظهور رغبة شديدة في التصرف بطرق لم تعتد عليها من قبل أو إن كنت لا تستطيع مقاومة الاندفاع والوسوسة للقيام بأفعال معينة يمكن أن تحمل الأذى لك أو لغيرك. يدعى ذلك اضطراب مقاومة الاندفاع (اضطراب التحكم بالانفعالات) والذي قد يشتمل على بعض السلوك الأخرى مثل: إدمان المقامرة، فرط الشهية، فرط الإنفاق، أو رغبة جنسية شديدة بشكل غير طبيعي أو الانشغال المتزايد بالأفكار والمشاعر الجنسية.</p><p dir="RTL">سيحتاج الطبيب حينها إلى التدخل لتعديل جرعتك من الدواء أو إيقافه.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقين:</strong></p><p dir="RTL">يجب عدم استخدام هذا الدواء من قبل الأطفال والمراهقين الأصغر من 13 عاما، لأنه من غير المعلوم إن كان آمنا وفعالا في هذه السن أم لا.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>تناول أدوية أخرى مع زورتا:</strong></p><p dir="RTL">يجب إخبار الطبيب أو الصيدليّ إذا كنت تتناول أدوية أخرى أو تناولت مؤخرًا بعض الأدوية أو تنوي تناول أي دواء آخر، بما في ذلك الأدوية التي تأتي بدون وصفة طبية.</p><p dir="RTL">الأدوية الخافضة لضغط الدم: قد يعمل <strong>زورتا</strong> على زيادة تأثير الأدوية التي تعمل على خفض ضغط الدم. كُن حريصا على إبلاغ الطبيب إذا كنت تتناول أي من الأدوية التي تعمل على التحكم في ضغط الدم.</p><p dir="RTL">تناولك لأدوية أخرى مع <strong>زورتا</strong> قد يتطلب من الطبيب تعديل جرعتك من زورتا أو من الأدوية الأخرى.</p><p dir="RTL"><u>يجب إبلاغ الطبيب فيما يتعلق بتناول الأدوية التالية:</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تعمل على التحكم في نظم القلب (مثل: كوينيدين، أميودارون، فليكينايد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الاكتئاب أو المستخلصات العشبية التي تستخدم في علاج الاكتئاب والقلق (مثل: فلوكزتين، باروكزتين، فينلافاكزين، نبتة سانت جونز .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للفطريات (مثل: كيتوكونازول، إنتراكونازول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية التي تستخدم في علاج العدوى بفيروس نقص المناعة البشري (مثل: إيفافيرينز، نيفيرابين، مثبطات إنزيم البروتياز؛ مثل: إنديفينار، ريتونافير).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الصرع المستخدمة في علاج التشنجات (مثل: كارباميزيبين، فينيتوين، فينوباربيتول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المضادات الحيوية التي تستخدم في علاج مرض السلّ (ريفابيوتين، ريفامبيسين).</p><p dir="RTL">يمكن أن تزيد هذه الأدوية من مخاطر الأعراض الجانبية أو تؤثر سلبا على فاعلية الدواء؛ لذلك إذا شعرت بأية أعراض غير طبيعية أثناء تناولك أحد هذه الأدوية مع دواء زورتا، فيجب حينها التوجه إلى الطبيب.</p><p dir="RTL">الأدوية التي تعمل على زيادة مستوى السيروتونين والتي تستخدم في علاج حالات الاكتئاب، اضطراب القلق / التوتر العام، اضطراب الوسواس القهري، الرهاب الاجتماعي، بالإضافة إلى الصداع النصفي والألم، مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تريبتان، ترامادول، تريبتوفان، المستخدمون في علاج حالات الاكتئاب، اضطراب القلق العام،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب الوسواس القهري، الرهاب الاجتماعي، بالإضافة إلى الصداع النصفي والألم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات السيروتونين الانتقائية (SSRIs) (مثل: باروكزيتين، فلوكزيتين) التي تستخدم في علاج الاكتئاب واضطراب الوسواس القهري ونوبات الفزع والقلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى مضادة للاكتئاب (مثل: فينلافاكزين، تريبتوفان) التي تستخدم في علاج حالات الاكتئاب الشديد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية ثلاثية الحلقات المضادة للاكتئاب (مثل: كلوميبرامين، أميتريبتالين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جونز (نبتة القديس يوحنا - نبتة العرن المثقوب) تستخدم كمستخلص عشبي لعلاج حالات الاكتئاب البسيطة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مسكنات الألم (مثل: ترامادول، بيثيدين) والتي تستخدم في تخفيف الألم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تربيتان (مثل: سوماتريبتان، زولميتريبتان) التي تستخدم في علاج الصداع النصفي</p><p dir="RTL">يمكن أن تزيد هذه الأدوية من مخاطر الأعراض الجانبية؛ لذلك إذا شعرت بأية أعراض غير طبيعية أثناء تناولك أحد هذه الأدوية مع دواء <strong>زورتا</strong>، فيجب حينها التوجه إلى الطبيب.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>تناول زورتا مع الطعام والمشروبات والكحوليات:</strong></p><p dir="RTL">يمكنك تناول هذا الدواء بصرف النظر عن موعد الوجبات.</p><p dir="RTL">يجب تجنب المشروبات الكحولية.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>تأثير الدواء على الحمل والرضاعة الطبيعية والخصوبة:</strong></p><p dir="RTL">يجب استشارة الطبيب أو الصيدلي قبل تناول هذا الدواء في حالة السيدات الحوامل أو اللاتي تقمن بالرضاعة الطبيعية أو في حالات التخطيط لحدوث الحمل أو إذا كنتِ تشعرين بالحمل.</p><p dir="RTL">يمكن أن يصاب الطفل المولود حديثا لأم تناولت هذا الدواء في الربع الأخير من الحمل (آخر 3 أشهر من الحمل) بالأعراض الآتية: الارتجاف / الارتعاش، تيبس العضلات و / أو ضعف العضلات، النعاس، الاضطراب، مشاكل في التنفس، صعوبة في الرضاعة. يجب التوجه إلى الطبيب إذا أصيب الطفل بأي من هذه الأعراض.</p><p dir="RTL">إذا كنت تتناولين دواء زورتا، فسيقوم الطبيب بمناقشتك بما ينبغي عليك فعله سواء كان الأفضل لك المتابعة على الدواء من أجل علاجك أو القيام بالرضاعة الطبيعية من أجل الطفل، حيث أنه من غير الممكن القيام بهما معا. توجهي بالسؤال إلى الطبيب فيما يتعلق بأفضل وسيلة لتغذية الطفل أثناء تناولك هذا الدواء.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات:</strong></p><p dir="RTL">يمكن أن تُصاب بالدوار أو بمشاكل في الرؤية أثناء تناولك هذا الدواء (برجاء الاطلاع على الفقرة الرابعة).</p><p dir="RTL">ينبغي أخذ ذلك في الاعتبار في الحالات التي تتطلب الانتباه الكامل مثل قيادة السيارة أو التعامل مع الآلات.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>يحتوي زورتا على اللاكتوز</strong></p><p dir="RTL">ينبغي استشارة الطبيب قبل تناول هذا الدواء إذا كان قد سبق وأخبرك الطبيب بعدم قدرتك على تحمل بعض أنواع السكر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب تناول هذا الدواء وفقًا لتعليمات الطبيب. يرجى التوجه بالسؤال للطبيب أو الصيدلي في حالة عدم تأكدك من الطريقة الصحيحة.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجرعة الموصى بها للبالغين هي 15 ملغم تؤخذ مرة في اليوم.</strong> وبالرغم من ذلك، فقد يصف لك الطبيب جرعة أٌقل أو على من ذلك حيث أن أقصى جرعة يمكن تناولها في اليوم هي 30 ملغم.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>استخدام الدواء مع الأطفال والمراهقين</strong></p><p dir="RTL">يمكن تناول هذا الدواء بجرعات قليلة في البداية على شكل محلول فموي (سائل).</p><p dir="RTL">على أن يتم رفع الجرعة بالتدريج إلى <strong>الجرعة الموصى بها للمراهقين وهي 10 ملغم تؤخذ مرة في اليوم</strong>. وبالرغم من ذلك، فقد يصف الطبيب جرعة أٌقل أو أعلى من ذلك حيث أن أقصى جرعة يمكن تناولها في اليوم هي 30 ملغم.</p><p dir="RTL">إذا كان لديك شعور بأن جرعتك من الدواء مرتفعة جدا أو منخفضة جدا، فيجب استشارة الطبيب لمعرفة إن كانت جرعتك تتطلب التعديل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ينصح بمحاولة تناول الدواء في نفس الوقت من كل اليوم.</strong> يمكنك تناول هذا الدواء مع الطعام أو بدونه. ينصح بتناول الدواء باستخدام الماء مع بلع القرص بأكمله.</p><p dir="RTL"><strong>لا تتوقف عن تناول الدواء حتى إذا شعرت بالتحسن</strong> ولا تغير جرعته أيضا، إلا إذا قمت باستشارة الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت جرعات من دواء زورتا أكثر من الموصى بها:</strong></p><p dir="RTL">يجب استشارة الطبيب على الفور إذا أدركت أنك قد تناولت جرعة أكبر من التي قد أوصى بها الطبيب (أو إذا تناول أحد غيرك بعضا من هذا الدواء). إذا لم تتمكن من الوصول إلى الطبيب، فيجب التوجه لأقرب مستشفى وقم بأخذ عبوة الدواء معك.</p><p dir="RTL"><u>الأعراض التي سيعاني منها المرضى الذين تناولوا جرعات عالية من مادة أريبيبرازول:&nbsp; </u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة نبضات القلب، التهيج والانفعال العصبي / العدوانية، مشاكل في التحدث.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات غير طبيعية (خاصة في الوجه واللسان) ونقص مستوى الوعي.</p><p dir="RTL"><u>قد يشمل الأمر أعراضًا أخرى مثل الآتي:</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك حاد، نوبات صرعية (تشنجات)، غيبوبة، مزيج من ارتفاع درجة الحرارة وسرعة التنفس والعرق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس العضلات، الشعور بالدوار أو النعاس، بطء التنفس، الاختناق، ارتفاع أو انخفاض ضغط الدم،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل في نظم القلب (نبضات غير طبيعية).</p><p dir="RTL">يجب التواصل فورا مع الطبيب إذا لاحظت أي من هذه الأعراض السابقة.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت تناول الدواء:</strong></p><p dir="RTL">إذا فاتك موعد الجرعة اليومية من الدواء، فيمكنك تناولها وقت تذكرك، ولكن يجب عليك عدم تناول جرعتين في يوم واحد.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا توقفت عن تناول الدواء:</strong></p><p dir="RTL">لا تتوقف عن تناول الدواء حتى إذا شعرت بالتحسن. يجب الاستمرار في تناول الدواء ما دام الطبيب يخبرك بذلك.</p><p dir="RTL">يرجى استشارة الطبيب أو الصيدلي إذا كانت لديك أية أسئلة إضافية فيما يتعلق بتناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كافة الأدوية، فإن هذا الدواء يمكن أن يتسبب في ظهور بعض الأعراض جانبية، وعلى الرغم من ذلك فإنها لا تظهر على جميع المرضى.</p><p dir="RTL"><u>الأعراض الجانبية المألوفة (تؤثر في 1 من بين 10 أشخاص):</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض السكر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالتوتر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالقلق وعدم القدرة على البقاء هادئًا وصعوبة الجلوس دون حركة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتعاش لا إرادي، حركات منتفضة أو ملتوية، عدم ثبات حركة الأقدام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتجاف / رعشة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبوط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالنعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتجاف وتشوش الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص في حركة الأمعاء أو صعوبة في حركة الأمعاء (إمساك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر هضم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالتعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; امتلاء الفم باللعاب بصورة أكثر من الطبيعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالإرهاق</p><p dir="RTL"><u>الأعراض الجانبية غير المألوفة (تؤثر في 1 من بين 100 شخص):</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستويات هرمون البرولاكتين في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة السكر في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير أو زيارة في الرغبة الجنسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات لا إرادية في الفم واللسان والأطراف (خلل الحركة المتأخر)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلال في العضلات مما ينتج عنه حركات ملتوية (اختلال في توتر العضلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ازدواج الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة سرعة ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم عند الوقوف مما يتسبب في الشعور بالدوخة والدوار أو الإغماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حازوقة</p><p dir="RTL">تمت الإفادة بحدوث الأعراض الجانبية الآتي ذكرها منذ بداية تسويق هذا الدواء ولكن ليست لدينا أية تقديرات لاحتمالية تكرار حدوث هذه الأعراض بين المرضى حتى الآن:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص عدد كرات الدم البيضاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص عدد الصفائح الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي / حساسية (تظهر في صورة تورم الوجه، تورم الشفاه، اللسان، الحلق، أو طفح الجلدي وشعور بالحكّة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدهور أو الإصابة بمرض السكر أو الحُمض الكيتوني (وجود الكيتون في البول) أو الدخول في غيبوبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة السكر في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نسبة الصوديوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفكار انتحارية، محاولة الانتحار أو الانتحار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالعدائية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهيج العصبي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاندفاع العصبي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مزيج من ارتفاع درجة الحرارة وسرعة التنفس والعرق ونقص مستوى الوعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات مفاجئة في ضغط الدم ومعدل ضربات القلب، الإغماء (متلازمة مضادات الذهان الخبيثة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات صرعية (تشنجات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة السيروتونين (والتي تتسبب في نوبات من السعادة الغامرة، الدوار، اللامبالاة، الاضطراب، الشعور بالسُّكر، ارتفاع درجة الحرارة، العرق، تصلب العضلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب الكلام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موت مفاجئ غير متوقع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب غير منتظمة تهدد الحياة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سكتة قلبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء في سرعة ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات في الأوردة خاصة في أوردة القدم (تشمل أعراضها الآتي: تورم وألم واحمرار في القدم) والتي من الممكن أن تسري في الدم عبر الأوعية الدموية حتى تصل إلى الرئة وتسبب ألم في الصدر وصعوبة في التنفس (إذا لاحظت أي من هذه الأعراض فيجب عليك طلب الرعاية الطبية فورا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلاع الطعام عن دون قصد مما قد يعرضك لخطر الإصابة بالالتهاب الرئوي (عدوى في الرئة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات في العضلات المحيطة بالحنجرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في البنكرياس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في البلع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بعدم الارتياح في البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بعدم الارتياح في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل كبدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار في الجلد أو العين (يرقان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقارير تفيد عن وجود اختلال في قيم اختبارات وظائف الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية للضوء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصلع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العرق بغزارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحلل غير طبيعي في العضلات مما قد يؤدي إلى مشاكل في الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان التحكم الإرادي في التبول (سلس البول)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التبول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور أعراض الانسحاب في الأطفال حديثي الولادة الذين تعرضوا للدواء أثناء فترة الحمل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتصاب مُطوّل و/أو مؤلم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التحكم في درجة حرارة الجسم الداخلية أو فرط السخونة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في اليد أو الكاحل أو القدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فحوصات الدم: زيادة أو تغير مستوى السكر في الدم، زيادة الهيموغلوبين السكري</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على مقاومة الاندفاع والوسوسة للقيام بأفعال معينة يمكن أن تحمل الأذى لك أو لغيرك، ويشمل ذلك الآتي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدافع القوي للمقامرة بشكل مفرط بالرغم من العواقب الشخيصة والعائلية الجسيمة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير أو زيادة في الرغبة الجنسية وظهور سلوك غير طبيعي بالنسبة لك أو لغيرك مثل الزيادة في الدافع الجنسي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط التسوق (الشراء) مع عدم القدرة على التحكم فيه.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأكل بشراهة (تناول كميات كبيرة من الطعام في مدة زمنية قصيرة) أو النّهم المرضي للأكل (تناول كميات كبيرة من الطعام أكثر من الطبيعي وأكثر مما تحتاجه للشبع)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرغبة في التجول بعيدا</p><p dir="RTL">يجب إبلاغ الطبيب إذا لاحظت أي من هذه السلوك والأعراض، على أن يقوم الطبيب بمناقشة الطرق المتاحة للتحكم أو التقليل من هذه الأعراض.</p><p dir="RTL">تمت الإفادة بوجود المزيد من الحالات المميتة في المرضى المتقدمين في السن الذين يعانون من فقدان الذكرة ويتناولون هذا الدواء. بالإضافة إلى ذلك، فقد تمت الإفادة بوجود حالات سكتة دماغية أو جلطات دماغية صغيرة.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأعراض الجانبية الإضافية التي قد تصيب الأطفال والمراهقين</strong></p><p dir="RTL">أصيب المراهقون الذين يبلغون من العمر 13 عاما فما فوق بأعراض جانبية مشابهة في النوع والتكرار لتلك الأعراض التي ظهرت في البالغين عدا أن الأعراض الآتية كانت بنسبة أكبر بكثير:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالنعاس وارتعاش لا إرادي، حركات منتفضة، اضطراب (كانت تلك الأعراض مألوفة جدا حيث حدثت في أكثر من 1 من بين 10 أشخاص).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في أعلى البطن وجفاف الفم وزيادة سرعة ضربات القلب وزيادة الوزن وزيادة الشهية وارتجاف العضلات والحركات اللا إرادية في الأطراف والشعور بالدوار خاصة عند القيام بعد الاستلقاء أو الجلوس (كانت تلك الأعراض مألوفة حيث حدثت في أكثر من 1 من بين 100 شخص)</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ الدواء بعيدا عن متناول الأطفال.</p><p dir="RTL">لا تستخدم الدواء بعد مرور تاريخ انتهاء الصلاحية الموضح على شريط الأقراص وعلى العبوة بعد كلمة EXP. &nbsp;يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير في الشهر.</p><p dir="RTL">لا تحفظ الدواء في درجة حرارة تزيد عن 30 درجة مئوية ، يستخدم الدواء في غضون 6 أشهر بعد الفتح لأول مرة.</p><p dir="RTL">لا تقم بإلقاء أية أدوية في مياه الصرف أو في النفايات المنزلية، وبدلاً عن ذلك قم باستشارة الصيدلي عن كيفية التخلص الآمن من الأدوية التي لم تعد في حاجة إليها. ستساعد هذه الإجراءات في المحافظة على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة: أريبيبرازول</p><p dir="RTL">يحتوي <strong>زورتا 10 ملغم</strong> على 10 ملغم من المادة الفعال أريبيبرازول.</p><p dir="RTL">يحتوي <strong>زورتا 15 ملغم</strong> على 15 ملغم من المادة الفعال أريبيبرازول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; باقي المكونات: لاكتوز أحادي الهيدرات، نشا الذرة، سليلوز دقيق البلورات هايدروكسي بروبيل سيليلوز، استيارات الماغنيسيوم، أكسيد الحديد الأحمر (<strong>زورتا 10 ملغم</strong> ) ، أكسيد الحديد الأصفر&nbsp; (<strong>زورتا 15 ملغم</strong> ) و المياه المقطرة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">زورتا 10 ملغم</p><p dir="RTL">أقراص وردية محدبة الشكل ومزخرفة بنقش بيضاوي منقوشة بـ &quot;N50&quot; على جانب واحد ومنبسط على الجانب الآخر.</p><p dir="RTL">زورتا 15 ملغم</p><p dir="RTL">أقراص صفراء محدبة الشكل &nbsp;مستديرة منقوشة بـ &quot;T22&quot; على جانب واحد ومنبسطة على الجانب الآخر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إم إس فارما السعودية</p><p dir="RTL">الرياض ، المملكة العربية السعودية .</p><p dir="RTL">info-ksa@mspharma.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>صنعت بواسطة </strong><strong>:</strong></p><p dir="RTL">المتحدة للصناعات الدوائية &ndash; الأردن <strong>لصالح </strong>إم إس فارما &ndash; المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسمبر ، 2020
SPM190361

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ZORTA  10 mg tablets
ZORTA  15 mg tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ZORTA  10 mg tablets
Each tablet contains 10 mg of aripiprazole.
ZORTA  15 mg tablets
Each tablet contains 15 mg of aripiprazole.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ZORTA  10 mg tablets
Pink, oval scored convex tablets embossed with “N50” on one side and plain on other side.
ZORTA  15 mg tablets
Yellow, round convex tablets embossed with “T22” on one side and plain on other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ZORTA &nbsp;is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.</p><p>ZORTA &nbsp;is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1).</p><p>ZORTA &nbsp;is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>Adults</u></p><p>Schizophrenia: the recommended starting dose for ZORTA &nbsp;is 10 or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals. ZORTA &nbsp;is effective in a dose range of 10 to 30 mg/day.</p><p>Enhanced efficacy at doses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher dose. The maximum daily dose should not exceed 30 mg.</p><p>Manic episodes in Bipolar I Disorder: the recommended starting dose for ZORTA &nbsp;is 15 mg administered on a once-aday schedule without regard to meals as monotherapy or combination therapy (see section 5.1). Some patients may benefit from a higher dose. The maximum daily dose should not exceed 30 mg.</p><p>Recurrence prevention of manic episodes in Bipolar I Disorder: for preventing recurrence of manic episodes in patients,</p><p>who have been receiving aripiprazole as monotherapy or combination therapy, continue therapy at the same dose.</p><p>Adjustments of daily dosage, including dose reduction should be considered on the basis of clinical status.</p><p>&nbsp;</p><p>Paediatric population</p><p>Schizophrenia in adolescents aged 15 years and older: the recommended dose for ZORTA &nbsp;is 10 mg/day administered on a once-a-day schedule without regard to meals. Treatment should be initiated at 2 mg (using ZORTA &nbsp;oral solution 1 mg/ml) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg. When appropriate, subsequent dose increases should be administered in 5 mg increments without exceeding the maximum daily dose of 30 mg (see section 5.1). ZORTA &nbsp;is effective in a dose range of 10 to 30 mg/day. Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated although individual patients may benefit from a higher dose.</p><p>ZORTA &nbsp;is not recommended for use in patients with schizophrenia below 15 years of age due to insufficient data on safety and efficacy (see sections 4.8 and 5.1).</p><p>Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older: the recommended dose for ZORTA &nbsp;is 10 mg/day administered on a once-a-day schedule without regard to meals. Treatment should be initiated at 2 mg (using ZORTA &nbsp;oral solution 1 mg/ml) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg. The treatment duration should be the minimum necessary for symptom control and must not exceed 12 weeks.</p><p>Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated, and a daily dose of 30 mg is associated with a substantially higher incidence of significant adverse reactions including EPS related events,</p><p>somnolence, fatigue and weight gain (see section 4.8). Doses higher than 10 mg/day should therefore only be used in exceptional cases and with close clinical monitoring (see sections 4.4, 4.8 and 5.1). Younger patients are at increased risk of experiencing adverse events associated with aripiprazole. Therefore, ZORTA &nbsp;is not recommended for use in patients below 13 years of age (see sections 4.8 and 5.1).</p><p>Irritability associated with autistic disorder: the safety and efficacy of ZORTA &nbsp;in children and adolescents aged below 18 years have not yet been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.</p><p>Tics associated with Tourette&#39;s disorder: the safety and efficacy of ZORTA &nbsp;in children and adolescents 6 to 18 years of age have not yet been established. Currently available data are described in section 5.1 but no recommendation on&nbsp; posology can be made.</p><p>&nbsp;</p><p><u>Special population</u></p><p><u>Hepatic impairment</u></p><p>No dosage adjustment is required for patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the data available are insufficient to establish recommendations. In these patients dosing should be managed cautiously. However, the maximum daily dose of 30 mg should be used with caution in patients with severe hepatic impairment (see section 5.2).</p><p><u>Renal impairment</u></p><p>No dosage adjustment is required in patients with renal impairment.</p><p><u>Elderly</u></p><p>The safety and efficacy of ZORTA &nbsp;in the treatment of schizophrenia or manic episodes in Bipolar I Disorder in patients aged 65 years and older has not been established. Owing to the greater sensitivity of this population, a lower starting dose should be considered when clinical factors warrant (see section 4.4).</p><p><u>Gender</u></p><p>No dosage adjustment is required for female patients as compared to male patients (see section 5.2).</p><p><u>Smoking status</u></p><p>According to the metabolic pathway of aripiprazole no dosage adjustment is required for smokers (see section 4.5).</p><p><u>Dose adjustments due to interactions</u></p><p>When concomitant administration of strong CYP3A4 or CYP2D6 inhibitors with aripiprazole occurs, the aripiprazole dose should be reduced. When the CYP3A4 or CYP2D6 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased (see section 4.5).</p><p>When concomitant administration of strong CYP3A4 inducers with aripiprazole occurs, the aripiprazole dose should be increased. When the CYP3A4 inducer is withdrawn from the combination therapy, the aripiprazole dose should then be reduced to the recommended dose (see section 4.5).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;ZORTA &nbsp;is for oral use.</p><p>Orodispersible tablets or oral solution may be used as an alternative to ZORTA &nbsp;tablets for patients who have difficulty swallowing ZORTA &nbsp;tablets (see section 5.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During antipsychotic treatment, improvement in the patient&#39;s clinical condition may take several days to some weeks. Patients should be closely monitored throughout this period.</p><p>&nbsp;</p><p><u>Suicidality </u></p><p>The occurrence of suicidal behavior is inherent in psychotic illnesses and mood disorders and in some cases has been reported early after initiation or switch of antipsychotic treatment, including treatment with aripiprazole (see section 4.8).</p><p>Close supervision of high-risk patients should accompany antipsychotic treatment.</p><p>&nbsp;</p><p><u>Cardiovascular disorders</u></p><p>Aripiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension, including accelerated or malignant. Cases of venous thromboembolism (VTE) have been reported with antipsychotic medicinal products. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with aripiprazole and preventive measures undertaken.</p><p>&nbsp;</p><p><u>QT prolongation</u></p><p>In clinical trials of aripiprazole, the incidence of QT prolongation was comparable to placebo. Aripiprazole should be used with caution in patients with a family history of QT prolongation (see section 4.8).</p><p>&nbsp;</p><p><u>Tardive dyskinesia</u></p><p>In clinical trials of one year or less duration, there were uncommon reports of treatment emergent dyskinesia during treatment with aripiprazole. If signs and symptoms of tardive dyskinesia appear in a patient on aripiprazole, dose reduction or discontinuation should be considered (see section 4.8). These symptoms can temporally deteriorate or can even arise after discontinuation of treatment.</p><p>&nbsp;</p><p><u>Other extrapyramidal symptoms</u></p><p>In paediatric clinical trials of aripiprazole akathisia and Parkinsonism were observed. If signs and symptoms of other EPS appear in a patient taking aripiprazole, dose reduction and close clinical monitoring should be considered.</p><p>&nbsp;</p><p><u>Neuroleptic Malignant Syndrome (NMS)</u></p><p>&nbsp;NMS is a potentially fatal symptom complex associated with antipsychotics. In clinical trials, rare cases of NMS were reported during treatment with aripiprazole. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. However, elevated creatine phosphokinase and rhabdomyolysis, not necessarily in association with NMS, have also been reported. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all antipsychotics, including aripiprazole, must be discontinued.</p><p>&nbsp;</p><p><u>Seizure</u></p><p>&nbsp;In clinical trials, uncommon cases of seizure were reported during treatment with aripiprazole. Therefore, aripiprazole should be used with caution in patients who have a history of seizure disorder or have conditions associated with seizures (see section 4.8).</p><p>&nbsp;</p><p><u>Elderly patients with dementia-related psychosis</u></p><p>Increased mortality</p><p>In three placebo-controlled trials (n = 938; mean age: 82.4 years; range: 56-99 years) of aripiprazole in elderly patients with psychosis associated with Alzheimer&#39;s disease, patients treated with aripiprazole were at increased risk of death compared to placebo. The rate of death in aripiprazole-treated patients was 3.5 % compared to 1.7 % in the placebo group. Although the causes of deaths were varied, most of the deaths appeared to be either cardiovascular (e.g. heart failure, sudden death) or infectious (e.g. pneumonia) in nature (see section 4.8).</p><p>Cerebrovascular adverse reactions</p><p>In the same trials, cerebrovascular adverse reactions (e.g. stroke, transient ischaemic attack), including fatalities, were reported in patients (mean age: 84 years; range: 78-88 years). Overall, 1.3 % of aripiprazole-treated patients</p><p>reported cerebrovascular adverse reactions compared with 0.6 % of placebo-treated patients in these trials. This difference was not statistically significant. However, in one of these trials, a fixed-dose trial, there was a significant dose response relationship for cerebrovascular adverse reactions in patients treated with aripiprazole (see section 4.8).</p><p>Aripiprazole is not indicated for the treatment of patients with dementia-related psychosis.</p><p><u>Hyperglycemia and diabetes mellitus </u></p><p>Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics, including aripiprazole. Risk factors that may predispose patients to severe complications include obesity and family history of diabetes. In clinical trials with aripiprazole, there were no significant differences in the incidence rates of hyperglycemia-related adverse reactions (including diabetes) or in abnormal glycaemia laboratory values compared to placebo. Precise risk estimates for hyperglycemia-related adverse reactions in patients treated with aripiprazole and with other atypical antipsychotics are not available to allow direct comparisons. Patients treated with any antipsychotics, including aripiprazole, should be observed for signs and symptoms of hyperglycemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section 4.8).</p><p><u>Hypersensitivity</u></p><p>Hypersensitivity reactions, characterized by allergic symptoms, may occur with aripiprazole (see section 4.8).</p><p>&nbsp;</p><p><u>Weight gain</u></p><p>Weight gain is commonly seen in schizophrenic and bipolar mania patients due to co-morbidities, use of antipsychotics ,known to cause weight gain, poorly managed life-style, and might lead to severe complications. Weight gain has been reported post-marketing among patients prescribed aripiprazole. When seen, it is usually in those with significant risk factors such as history of diabetes, thyroid disorder or pituitary adenoma. In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain in adults (see section 5.1). In clinical trials of adolescent patients with bipolar mania, aripiprazole has been shown to be associated with weight gain after 4 weeks of treatment. Weight gain should be monitored in adolescent patients with bipolar mania. If weight gain is clinically significant, dose reduction should be considered (see section 4.8).</p><p>&nbsp;</p><p><u>Dysphagia</u></p><p>Oesophageal dysmotility and aspiration have been associated with the use of antipsychotics, including aripiprazole.</p><p>Aripiprazole should be used cautiously in patients at risk for aspiration pneumonia.</p><p>&nbsp;</p><p><u>Pathological gambling and other impulse control disorders</u></p><p>Patients can experience increased urges, particularly for gambling, and the inability to control these urges while taking aripiprazole. Other urges, reported, include: increased sexual urges, compulsive shopping, binge or compulsive eating, and other impulsive and compulsive behaviors. It is important for prescribers to ask patients or their caregivers specifically about the development of new or increased gambling urges, sexual urges, compulsive shopping, binge or compulsive eating, or other urges while being treated with aripiprazole. It should be noted that impulse-control symptoms can be associated with the underlying disorder; however, in some cases, urges were reported to have stopped when the dose was reduced or the medication was discontinued. Impulse control disorders may result in harm to the patient and others if not recognized. Consider dose reduction or stopping the medication if a patient develops such urges while taking aripiprazole (see section 4.8).</p><p>&nbsp;</p><p><u>Lactose</u></p><p>ZORTA &nbsp;tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the lapp lactase</p><p>deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p><p><u>Patients with ADHD comorbidity.</u></p><p>Despite the high comorbidity frequency of Bipolar I Disorder and ADHD, very limited safety data are available on concomitant use of aripiprazole and stimulants; therefore, extreme caution should be taken when these medicinal products are co-administered.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to its &alpha;1-adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain</p><p>antihypertensive medicinal products.</p><p>Given the primary CNS effects of aripiprazole, caution should be used when aripiprazole is administered in combination with alcohol or other CNS medicinal products with overlapping adverse reactions such as sedation (see section 4.8).</p><p>If aripiprazole is administered concomitantly with medicinal products known to cause QT prolongation or electrolyte imbalance, caution should be used.</p><p>Potential for other medicinal products to affect aripiprazole</p><p>A gastric acid blocker, the H2 antagonist famotidine, reduces aripiprazole rate of absorption but this effect is deemed not clinically relevant. Aripiprazole is metabolized by multiple pathways involving the CYP2D6 and CYP3A4 enzymes but not CYP1A enzymes. Thus, no dosage adjustment is required for smokers.</p><p>&nbsp;</p><p><u>Quinidine and other CYP2D6 inhibitors</u></p><p>In a clinical trial in healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107 %, while Cmax was unchanged. The AUC and Cmax of dehydro-aripiprazole, the active metabolite, decreased by 32 % and 47 %, respectively. Aripiprazole dose should be reduced to approximately one-half of its prescribed dose when concomitant administration of aripiprazole with quinidine occurs. Other strong inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar effects and similar dose reductions should therefore be applied.</p><p>&nbsp;</p><p><u>Ketoconazole and other CYP3A4 inhibitors</u></p><p>In a clinical trial in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and Cmax by 63 % and 37 %, respectively. The AUC and Cmax of dehydro-aripiprazole increased by 77 % and 43 %, respectively.</p><p>In CYP2D6 poor metabolizers, concomitant use of strong inhibitors of CYP3A4 may result in higher plasma</p><p>concentrations of aripiprazole compared to that in CYP2D6 extensive metabolizers. When considering concomitant administration of ketoconazole or other strong CYP3A4 inhibitors with aripiprazole, potential benefits should outweigh the potential risks to the patient. When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to approximately one-half of its prescribed dose. Other strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors may be expected to have similar effects and similar dose reductions should therefore be applied (see section 4.2). Upon discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should be increased to the level prior to the initiation of the concomitant therapy. When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g. escitalopram) are used concomitantly with aripiprazole, modest increases in plasma aripiprazole concentrations may be expected.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Carbamazepine and other CYP3A4 inducers</u></p><p>Following concomitant administration of carbamazepine, a strong inducer of CYP3A4, and oral aripiprazole to patients with schizophrenia or schizoaffective disorder, the geometric means of Cmax and AUC for aripiprazole were 68 % and 73 % lower, respectively, compared to when aripiprazole (30 mg) was administered alone. Similarly, for dehydro-aripiprazole the geometric means of Cmax and AUC after carbamazepine co-administration were 69 % and 71 % lower, respectively, than those following treatment with aripiprazole alone. Aripiprazole dose should be doubled when concomitant administration of aripiprazole occurs with carbamazepine. Concomitant administration of aripiprazole and other inducers of CYP3A4 (such as rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz, nevirapine and St. John&#39;s Wort) may be expected to have similar effects and similar dose increases should therefore be applied. Upon discontinuation of strong CYP3A4 inducers, the dosage of aripiprazole should be reduced to the recommended dose.</p><p>&nbsp;</p><p><u>Valproate and lithium</u></p><p>When either valproate or lithium was administered concomitantly with aripiprazole, there was no clinically significant change in aripiprazole concentrations and therefore no dose adjustment is necessary when either valproate or lithium is administered with aripiprazole.</p><p>&nbsp;</p><p><u>Potential for aripiprazole to affect other medicinal products </u></p><p>In clinical studies, 10-30 mg/day doses of aripiprazole had no significant effect on the metabolism of substrates of</p><p>CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan). Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2- mediated metabolism in vitro. Thus, aripiprazole is unlikely to cause clinically important medicinal product interactions mediated by these enzymes.</p><p>When aripiprazole was administered concomitantly with either valproate, lithium or lamotrigine, there was no clinically important change in valproate, lithium or lamotrigine concentrations.</p><p>&nbsp;</p><p><u>Serotonin syndrome</u></p><p>Cases of serotonin syndrome have been reported in patients taking aripiprazole, and possible signs and symptoms for this condition can occur especially in cases of concomitant use with other serotonergic medicinal products, such as SSRI/SNRI, or with medicinal products that are known to increase aripiprazole concentrations (see section 4.8).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate and well-controlled trials of aripiprazole in pregnant women. Congenital anomalies have been reported; however, causal relationship with aripiprazole could not be established. Animal studies could not exclude potential developmental toxicity (see section 5.3). Patients must be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with aripiprazole. Due to insufficient safety information in humans and concerns raised by animal reproductive studies, this medicinal product should not be used in pregnancy unless the expected benefit clearly justifies the potential risk to the fetus.</p><p>Newborn infants exposed to antipsychotics (including aripiprazole) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypertonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborn infants should be monitored carefully (see section 4.8).</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Aripiprazole is excreted in human milk. A decision must be made whether to discontinue breast-feeding or to</p><p>discontinue/abstain from aripiprazole therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Aripiprazole did not impair fertility based on data from reproductive toxicity studies.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aripiprazole has minor to moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred, diplopia (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most commonly reported adverse reactions in placebo-controlled trials were akathisia and nausea each occurring in more than 3 % of patients treated with oral aripiprazole.</p><p><u>Tabulated list of adverse reactions </u></p><p>The incidences of the Adverse Drug Reactions (ADRs) associated with aripiprazole therapy are tabulated below. The table is based on adverse events reported during clinical trials and/or post-marketing use.</p><p>All ADRs are listed by system organ class and frequency; very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>The frequency of adverse reactions reported during post-marketing use cannot be determined as they are derived from spontaneous reports. Consequently, the frequency of these adverse events is qualified as &quot;not known&quot;.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Leukopenia</p><p>Neutropenia</p><p>Thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Allergic reaction (e.g. anaphylactic reaction, angioedema including swollen tongue, tongue oedema, face oedema, pruritus, or urticaria)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hyperprolactinaemia</p></td><td style="vertical-align:top"><p>Diabetic hyperosmolar coma</p><p>Diabetic ketoacidosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Diabetes mellitus</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>Hyponatremia</p><p>Anorexia</p><p>Weight decreased</p><p>Weight gain</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>Insomnia</p><p>Anxiety</p><p>Restlessness</p></td><td style="vertical-align:top"><p>Depression,</p><p>Hypersexuality</p></td><td style="vertical-align:top"><p>Suicide attempt, suicidal ideation and completed suicide (see section 4.4)</p><p>Pathological gambling</p><p>Impulse-control disorders</p><p>Binge eating</p><p>Compulsive shopping</p><p>Poriomania</p><p>Aggression</p><p>Agitation</p><p>Nervousness</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Akathisia</p><p>Extrapyramidal disorder</p><p>Tremor</p><p>Headache</p><p>Sedation</p><p>Somnolence</p><p>Dizziness</p></td><td style="vertical-align:top"><p>Tardive dyskinesia</p><p>Dystonia</p></td><td style="vertical-align:top"><p>Neuroleptic Malignant Syndrome (NMS)</p><p>Grand mal convulsion</p><p>Serotonin syndrome</p><p>Speech disorder</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>Vision blurred</p></td><td style="vertical-align:top"><p>Diplopia</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>Sudden unexplained death</p><p>Torsades de pointes</p><p>QT prolongation</p><p>Ventricular arrhythmias</p><p>Cardiac arrest</p><p>Bradycardia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Orthostatic hypotension</p></td><td style="vertical-align:top"><p>Venous thromboembolism (including pulmonary embolism and deep vein thrombosis)</p><p>Hypertension</p><p>Syncope</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hiccups</p></td><td style="vertical-align:top"><p>Aspiration pneumonia</p><p>Laryngospasm</p><p>Oropharyngeal spasm</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Constipation</p><p>Dyspepsia</p><p>Nausea</p><p>Salivary hypersecretion</p><p>Vomiting</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Pancreatitis</p><p>Dysphagia</p><p>Diarrhoea</p><p>Abdominal discomfort</p><p>Stomach discomfort</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hepatic failure</p><p>Hepatitis</p><p>Jaundice</p><p>Increased Alanine Aminotransferase (ALT)</p><p>Increased Aspartate Aminotransferase (AST)</p><p>Increased Gamma Glutamyl Transferase (GGT)</p><p>Increased alkaline phosphatase</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash</p><p>Photosensitivity reaction</p><p>Alopecia</p><p>Hyperhidrosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rhabdomyolysis</p><p>Myalgia</p><p>Stiffness</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Urinary incontinence</p><p>Urinary retention</p></td></tr><tr><td style="vertical-align:top"><p><strong>Pregnancy, puerperium and perinatal conditions</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Drug withdrawal syndrome neonatal (see section 4.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Priapism</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Temperature regulation disorder (e.g. hypothermia, pyrexia)</p><p>Chest pain</p><p>Peripheral oedema</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Blood glucose increased</p><p>Glycosylated haemoglobin increased</p><p>Blood glucose fluctuation</p><p>Increased creatine phosphokinase</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><u>Adults</u></p><p>Extrapyramidal symptoms (EPS)</p><p>Schizophrenia: in a long term 52-week controlled trial, aripiprazole-treated patients had an overall-lower incidence (25.8 %) of EPS including Parkinsonism, akathisia, dystonia and dyskinesia compared with those treated with haloperidol (57.3 %). In a long term 26-week placebo-controlled trial, the incidence of EPS was 19 % for aripiprazole-treated patients and 13.1 % for placebo-treated patients. In another long-term 26-week controlled trial, the incidence of EPS was 14.8 % for aripiprazole-treated patients and 15.1 % for olanzapine-treated patients.</p><p>Manic episodes in Bipolar I Disorder: in a 12-week controlled trial, the incidence of EPS was 23.5 % for aripiprazole treated patients and 53.3 % for haloperidol-treated patients. In another 12-week trial, the incidence of EPS was 26.6 % for patients treated with aripiprazole and 17.6 % for those treated with lithium. In the long term 26-week maintenance phase of a placebo-controlled trial, the incidence of EPS was 18.2 % for aripiprazole-treated patients and 15.7 % for placebo-treated patients.</p><p>Akathisia</p><p>In placebo-controlled trials, the incidence of akathisia in bipolar patients was 12.1 % with aripiprazole and 3.2 % with placebo. In schizophrenia patients the incidence of akathisia was 6.2 % with aripiprazole and 3.0 % with placebo.</p><p>Dystonia</p><p>Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible</p><p>individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic medicinal products. An elevated risk of acute dystonia is observed in males and younger age groups.</p><p>Prolactin</p><p>In clinical trials for the approved indications and post-marketing, both increase and decrease in serum prolactin as compared to baseline was observed with aripiprazole (section 5.1).</p><p>Laboratory parameters</p><p>Comparisons between aripiprazole and placebo in the proportions of patients experiencing potentially clinically</p><p>significant changes in routine laboratory and lipid parameters (see section 5.1) revealed no medically important</p><p>differences. Elevations of CPK (Creatine Phosphokinase), generally transient and asymptomatic, were observed in 3.5 % of aripiprazole treated patients as compared to 2.0 % of patients who received placebo.</p><p>&nbsp;</p><p><u>Paediatric population </u></p><p>Schizophrenia in adolescents aged 15 years and older</p><p>In a short-term placebo-controlled clinical trial involving 302 adolescents (13-17 years) with schizophrenia, the frequency and type of adverse reactions were similar to those in adults except for the following reactions that were reported more frequently in adolescents receiving aripiprazole than in adults receiving aripiprazole (and more frequently than placebo):</p><p>Somnolence/sedation and extrapyramidal disorder were reported very commonly (&ge; 1/10), and dry mouth, increased appetite, and orthostatic hypotension were reported commonly (&ge; 1/100, &lt; 1/10). The safety profile in a 26-week openlabel extension trial was similar to that observed in the short-term, placebo-controlled trial.</p><p>The safety profile of a long-term, double-blind placebo controlled trial was also similar except for the following reactions that were reported more frequently than paediatric patients taking placebo: weight decreased, blood insulin increased, arrhythmia, and leukopenia were reported commonly (&ge; 1/100, &lt; 1/10).</p><p>In the pooled adolescent schizophrenia population (13-17 years) with exposure up to 2 years, incidence of low serum prolactin levels in females (&lt;3 ng/ml) and males (&lt; 2 ng/ml) was 29.5 % and 48.3 %, respectively. In the adolescent (13- 17 years) schizophrenia population with aripiprazole exposure of 5 to 30 mg up to 72 months, incidence of low serum prolactin levels in females (&lt;3 ng/ml) and males (&lt; 2 ng/ml) was 25.6 % and 45.0 %, respectively.</p><p>In two long term trials with adolescent (13-17 years) schizophrenia and bipolar patients treated with aripiprazole, incidence of low serum prolactin levels in females (&lt; 3 ng/ml) and males (&lt; 2 ng/ml) was 37.0 % and 59.4 %, respectively.</p><p>Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older</p><p>The frequency and type of adverse reactions in adolescents with Bipolar I Disorder were similar to those in adults except for the following reactions: very commonly (&ge; 1/10) somnolence (23.0 %), extrapyramidal disorder (18.4 %), akathisia (16.0 %), and fatigue (11.8 %); and commonly (&ge; 1/100, &lt; 1/10) abdominal pain upper, heart rate increased, weight increased, increased appetite, muscle twitching, and dyskinesia.</p><p>The following adverse reactions had a possible dose response relationship; extrapyramidal disorder (incidences were 10 mg, 9.1 %, 30 mg, 28.8 %, placebo, 1.7 %,); and akathisia (incidences were 10 mg, 12.1 %, 30 mg, 20.3 %, placebo, 1.7%).</p><p>Mean changes in body weight in adolescents with Bipolar I Disorder at 12 and 30 weeks for aripiprazole were 2.4 kg and 5.8 kg, and for placebo 0.2 kg and 2.3 kg, respectively.</p><p>In the paediatric population somnolence and fatigue were observed more frequently in patients with bipolar disorder compared to patients with schizophrenia.</p><p>In the paediatric bipolar population (10-17 years) with exposure up to 30 weeks, incidence of low serum prolactin levels in females (&lt; 3 ng/ml) and males (&lt; 2 ng/ml) was 28.0 % and 53.3 %, respectively.</p><p>Pathological gambling and other impulse control disorders</p><p>Pathological gambling, hypersexuality, compulsive shopping and binge or compulsive eating can occur in patients</p><p>treated with aripiprazole (see section 4.4).</p><p>Reporting of suspected adverse reactions.</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued.</p><p><strong>To reports any side effect(s):</strong></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;margin-left:.75pt;margin-top:7.3pt;
 width:375.05pt;height:90.75pt;z-index:251659264;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-align:left;mso-layout-grid-align:none;
    text-autospace:none;direction:ltr;unicode-bidi:embed'><span
    style='font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>-
    The National Pharmacovigilance and Drug Safety Centre (NPC) :<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;mso-list:l0 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Fax:
    +966-11-205-7662<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:
    l0 level1 lfo1;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Toll free
    phone: 19999<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:
    l0 level1 lfo1;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>E-mail:
    npc.drug@sfda.gov.sa<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpLast style='text-indent:-.25in;mso-list:l0 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Website: </span><span
    style='font-family:"Times New Roman",serif'>https://ade.sfda.gov.sa</span><span
    style='font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL style='text-indent:-.25in'><span dir=LTR><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><img width="506" height="127" alt="Text Box: - The National Pharmacovigilance and Drug Safety Centre (NPC) :
•	Fax: +966-11-205-7662
•	Toll free phone: 19999
•	E-mail: npc.drug@sfda.gov.sa
•	Website: https://ade.sfda.gov.sa

" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Signs and symptoms</u></p><p>In clinical trials and post-marketing experience, accidental or intentional acute overdose of aripiprazole alone was identified in adult patients with reported estimated doses up to 1,260 mg with no fatalities. The potentially medically important signs and symptoms observed included lethargy, increased blood pressure, somnolence, tachycardia, nausea,</p><p>vomiting and diarrhea. In addition, reports of accidental overdose with aripiprazole alone (up to 195 mg) in children have been received with no fatalities. The potentially medically serious signs and symptoms reported included somnolence, transient loss of consciousness and extrapyramidal symptoms.</p><p><u>Management of overdose:</u></p><p>Management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. The possibility of multiple medicinal product involvement should be considered. Therefore cardiovascular monitoring should be started immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias. Following any confirmed or suspected overdose with aripiprazole, close medical supervision and monitoring should continue until the patient recovers.</p><p>Activated charcoal (50 g), administered one hour after aripiprazole, decreased aripiprazole Cmax by about 41 % and AUC by about 51 %, suggesting that charcoal may be effective in the treatment of overdose.</p><p><u>Haemodialysis </u></p><p>Although there is no information on the effect of haemodialysis in treating an overdose with aripiprazole, haemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1 Pharmacodynamic properties</strong></p><p>Pharmacotherapeutic group: Psycholeptics, other antipsychotics, ATC code: N05AX12</p><p><u>Mechanism of action</u></p><p>&nbsp;It has been proposed that aripiprazole&#39;s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism of serotonin 5-HT2A receptors. Aripiprazole exhibited antagonist properties in animal models of dopaminergic hyperactivity and agonist properties in animal models of dopaminergic hypoactivity. Aripiprazole exhibited high binding affinity in vitro for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors and moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7,</p><p>alpha-1 adrenergic and histamine H1 receptors. Aripiprazole also exhibited moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptors. Interaction with receptors other than dopamine and serotonin subtypes may explain some of the other clinical effects of aripiprazole.</p><p>Aripiprazole doses ranging from 0.5 to 30 mg administered once a day to healthy subjects for 2 weeks produced a dose dependent reduction in the binding of 11C-raclopride, a D2/D3 receptor ligand, to the caudate and putamen detected by positron emission tomography.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety:</u></p><p><u>Adults</u></p><p>Schizophrenia</p><p>In three short-term (4 to 6 weeks) placebo-controlled trials involving 1,228 schizophrenic adult patients, presenting with positive or negative symptoms, aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo.</p><p>Aripiprazole is effective in maintaining the clinical improvement during continuation therapy in adult patients who have shown an initial treatment response. In a haloperidol-controlled trial, the proportion of responder patients maintaining response to medicinal product at 52-weeks was similar in both groups (aripiprazole 77 % and haloperidol 73 %). The overall completion rate was significantly higher for patients on aripiprazole (43 %) than for haloperidol (30 %).</p><p>&nbsp;Actual scores in rating scales used as secondary endpoints, including PANSS and the Montgomery-Asberg Depression Rating Scale showed a significant improvement over haloperidol.</p><p>In a 26-week, placebo-controlled trial in adult stabilized patients with chronic schizophrenia, aripiprazole had significantly greater reduction in relapse rate, 34 % in aripiprazole group and 57 % in placebo.</p><p>Weight gain</p><p>In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain. In a 26-week, olanzapine controlled,</p><p>double-blind, multi-national study of schizophrenia which included 314 adult patients and where the primary</p><p>end-point was weight gain, significantly less patients had at least 7 % weight gain over baseline (i.e. a gain of at least 5.6 kg for a mean baseline weight of ~80.5 kg) on aripiprazole (n = 18, or 13 % of evaluable patients), compared to olanzapine (n = 45, or 33 % of evaluable patients).</p><p>Lipid parameters</p><p>In a pooled analysis on lipid parameters from placebo controlled clinical trials in adults, aripiprazole has not been shown to induce clinically relevant alterations in levels of total cholesterol, triglycerides, HDL and LDL.</p><p>Prolactin</p><p>Prolactin levels were evaluated in all trials of all doses of aripiprazole (n = 28,242). The incidence of hyperprolactinemia or increased serum prolactin in patients treated with aripiprazole (0.3 %) was similar to that of placebo (0.2 %). For patients receiving aripiprazole, the median time to onset was 42 days and median duration was 34 days.</p><p>The incidence of hyperprolactinemia or decreased serum prolactin in patients treated with aripiprazole was 0.4 %,</p><p>compared with 0.02 % for patients treated with placebo. For patients receiving aripiprazole, the median time to onset was 30 days and median duration was 194 days.</p><p>Manic episodes in Bipolar I Disorder</p><p>In two 3-week, flexible-dose, placebo-controlled monotherapy trials involving patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole demonstrated superior efficacy to placebo in reduction of manic symptoms over 3 weeks.</p><p>These trials included patients with or without psychotic features and with or without a rapid-cycling course.</p><p>In one 3-week, fixed-dose, placebo-controlled monotherapy trial involving patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole failed to demonstrate superior efficacy to placebo.</p><p>In two 12-week, placebo- and active-controlled monotherapy trials in patients with a manic or mixed episode of Bipolar I Disorder, with or without psychotic features, aripiprazole demonstrated superior efficacy to placebo at week 3 and a maintenance of effect comparable to lithium or haloperidol at week 12. Aripiprazole also demonstrated a comparable proportion of patients in symptomatic remission from mania as lithium or haloperidol at week 12.</p><p>In a 6-week, placebo-controlled trial involving patients with a manic or mixed episode of Bipolar I Disorder, with or without psychotic features, who were partially non-responsive to lithium or valproate monotherapy for 2 weeks at therapeutic serum levels, the addition of aripiprazole as adjunctive therapy resulted in superior efficacy in reduction of manic symptoms than lithium or valproate monotherapy.</p><p>In a 26-week, placebo-controlled trial, followed by a 74-week extension, in manic patients who achieved remission on aripiprazole during a stabilization phase prior to randomization, aripiprazole demonstrated superiority over placebo in preventing bipolar recurrence, primarily in preventing recurrence into mania but failed to demonstrate superiority over placebo in preventing recurrence into depression.</p><p>In a 52-week, placebo-controlled trial, in patients with a current manic or mixed episode of Bipolar I Disorder who achieved sustained remission (Y-MRS and MADRS total scores &le; 12) on aripiprazole (10 mg/day to 30 mg/day) adjunctive to lithium or valproate for 12 consecutive weeks, adjunctive aripiprazole demonstrated superiority over placebo with a 46 % decreased risk (hazard ratio of 0.54) in preventing bipolar recurrence and a 65 % decreased risk (hazard ratio of 0.35) in preventing recurrence into mania over adjunctive placebo but failed to demonstrate superiority over placebo in preventing recurrence into depression. Adjunctive aripiprazole demonstrated superiority over placebo on the secondary outcome measure, CGI-BP Severity of Illness score (mania). In this trial, patients were assigned by investigators with either open-label lithium or valproate monotherapy to determine partial non-response. Patients were stabilized for at least 12 consecutive weeks with the combination of aripiprazole and the same mood stabilizer. Stabilized patients were then randomized to continue the same mood stabilizer with double-blind aripiprazole or placebo. Four mood stabilizer subgroups were assessed in the randomized phase: aripiprazole + lithium; aripiprazole + valproate; placebo + lithium; placebo + valproate. The Kaplan-Meier rates for recurrence to any mood episode for the adjunctive treatment arm were 16 % in aripiprazole + lithium and 18 % in aripiprazole + valproate compared to 45 % in placebo + lithium and 19 % in placebo + valproate.</p><p><u>Pediatric population</u></p><p>Schizophrenia in adolescents</p><p>In a 6-week placebo-controlled trial involving 302 schizophrenic adolescent patients (13-17 years), presenting with positive or negative symptoms, aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo. In a sub-analysis of the adolescent patients between the ages of 15 to 17 years, representing 74 % of the total enrolled population, maintenance of effect was observed over the 26-week open label extension trial.</p><p>In a 60- to 89-week, randomized, double-blind, placebo-controlled trial in adolescent subjects (n = 146; ages 13-17 years) with schizophrenia, there was a statistically significant difference in the rate of relapse of psychotic symptoms between the aripiprazole (19.39 %) and placebo (37.50 %) groups. The point estimate of the hazard ratio (HR) was 0.461 (95% confidence interval, 0.242-0.879) in the full population. In subgroup analyses the point estimate of the HR was 0.495 for subjects 13 to 14 years of age compared to 0.454 for subjects 15 to 17 years of age. However, the estimation of the HR for the younger (13-14 years) group was not precise, reflecting the smaller number of subjects in that group (aripiprazole, n = 29; placebo, n = 12), and the confidence interval for this estimation (ranging from 0.151 to 1.628) did not allow conclusions to be drawn on the presence of a treatment effect. In contrast the 95 % confidence interval for the HR in the older subgroup (aripiprazole, n = 69; placebo, n = 36) was 0.242 to 0.879 and hence a treatment effect could be concluded in the older patients.</p><p>&nbsp;</p><p>Manic episodes in Bipolar I Disorder in children and adolescents</p><p>Aripiprazole was studied in a 30-week placebo-controlled trial involving 296 children and adolescents (10-17 years), who met DSM-IV criteria for Bipolar I Disorder with manic or mixed episodes with or without psychotic features and had a YMRS score &ge; 20 at baseline. Among the patients included in the primary efficacy analysis, 139 patients had a current comorbid diagnosis of ADHD.</p><p>Aripiprazole was superior to placebo in change from baseline at week 4 and at week 12 on the Y-MRS total score. In a post-hoc analysis, the improvement over placebo was more pronounced in the patients with associated co-morbidity of ADHD compared to the group without ADHD, where there was no difference from placebo. Recurrence prevention was not established.</p><p>The most common treatment-emergent adverse events among patients receiving 30 mg were extrapyramidal disorder (28.3 %), somnolence (27.3 %), headache (23.2 %), and nausea (14.1 %). Mean weight gain in the 30 weeks treatment interval was 2.9 kg as compared to 0.98 kg in patients treated with placebo.</p><p>&nbsp;</p><p>Irritability associated with autistic disorder in pediatric patients (see section 4.2)</p><p>Aripiprazole was studied in patients aged 6 to 17 years in two 8-week, placebo-controlled trials [one flexible-dose (2-15 mg/day) and one fixed-dose (5, 10, or 15 mg/day)] and in one 52-week open-label trial. Dosing in these trials was initiated at 2 mg/day, increased to 5 mg/day after one week, and increased by 5 mg/day in weekly increments to the target dose. Over 75 % of patients were less than 13 years of age. Aripiprazole demonstrated statistically superior efficacy compared to placebo on the Aberrant Behavior Checklist Irritability subscale. However, the clinical relevance of this finding has not been established. The safety profile included weight gain and changes in prolactin levels. The duration of the long-term safety study was limited to 52 weeks. In the pooled trials, the incidence of low serum prolactin levels in females (&lt; 3 ng/ml) and males (&lt; 2 ng/ml) in aripiprazole-treated patients was 27/46 (58.7 %) and 258/298 (86.6 %), respectively. In the placebo-controlled trials, the mean weight gain was 0.4 kg for placebo and 1.6 kg for aripiprazole.</p><p>Aripiprazole was also studied in a placebo-controlled, long-term maintenance trial. After a 13-26 week stabilization on aripiprazole (2-15 mg/day) patients with a stable response were either maintained on aripiprazole or substituted to placebo for further 16 weeks. Kaplan-Meier relapse rates at week 16 were 35 % for aripiprazole and 52 % for placebo; the hazard ratio for relapse within 16 weeks (aripiprazole/placebo) was 0.57 (non-statistically significant difference). The mean weight gain over the stabilization phase (up to 26 weeks) on aripiprazole was 3.2 kg, and a further mean increase of 2.2 kg for aripiprazole as compared to 0.6 kg for placebo was observed in the second phase (16 weeks) of the trial.</p><p>Extrapyramidal symptoms were mainly reported during the stabilization phase in 17 % of patients, with tremor</p><p>accounting for 6.5 %.</p><p>&nbsp;</p><p>Tics associated with Tourette&#39;s disorder in pediatric patients (see section 4.2)</p><p>The efficacy of aripiprazole was studied in pediatric subjects with Tourette&#39;s disorder (aripiprazole: n = 99, placebo: n = 44) in a randomized, double-blind, placebo controlled, 8 week study using a fixed dose weight-based treatment group design over the dose range of 5 mg/day to 20 mg/day and a starting dose of 2 mg. Patients were 7 - 17 years of age and presented an average score of 30 on Total Tic Score on the Yale Global Tic Severity Scale (TTS-YGTSS) at baseline.</p><p>Aripiprazole showed an improvement on TTS-YGTSS change from baseline to week 8 of 13.35,for the low dose group (5 mg or 10 mg) and 16.94 for the high dose group (10 mg or 20 mg) as compared with an improvement of 7.09 in the placebo group.</p><p>The efficacy of aripiprazole in pediatric subjects with Tourette&#39;s syndrome (aripiprazole: n = 32, placebo: n = 29) was also evaluated over a flexible dose range of 2 mg/day to 20 mg/day and a starting dose of 2 mg, in a 10 week,</p><p>randomized, double blind, placebo-controlled study conducted in South-Korea. Patients were 6 - 18 years and presented an average score of 29 on TTS-YGTSS at baseline. Aripiprazole group showed an improvement of 14.97 on TTSYGTSS change from baseline to week 10 as compared with an improvement of 9.62 in the placebo group.</p><p>In both of these short term trials, the clinical relevance of the efficacy findings has not been established, considering the magnitude of treatment effect compared to the large placebo effect and the unclear effects regarding psycho-social functioning. No long term data are available with regard to the efficacy and the safety of aripiprazole in this fluctuating disorder.</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with ZORTA &nbsp;in one or more subsets of the pediatric population in the treatment of schizophrenia and in the treatment of bipolar affective disorder (see section 4.2 for information on pediatric use).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3-5 hours after dosing. Aripiprazole undergoes minimal pre-systemic metabolism. The absolute oral bioavailability of the tablet formulation is 87 %. There is no effect of a high fat meal on the pharmacokinetics of aripiprazole.</p><p><u>Distribution </u></p><p>Aripiprazole is widely distributed throughout the body with an apparent volume of distribution of 4.9 l/kg, indicating extensive extravascular distribution. At therapeutic concentrations, aripiprazole and dehydro-aripiprazole are greater than 99 % bound to serum proteins, binding primarily to albumin.</p><p><u>Biotransformation</u>:</p><p>Aripiprazole is extensively metabolized by the liver primarily by three biotransformation pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on in vitro studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4. Aripiprazole is the predominant medicinal product moiety in systemic circulation. At steady state, dehydro-aripiprazole, the active metabolite, represents about 40 % of aripiprazole AUC in plasma.</p><p><u>Elimination:</u></p><p>The mean elimination half-lives for aripiprazole are approximately 75 hours in extensive metabolizers of CYP2D6 and approximately 146 hours in poor metabolizers of CYP2D6.</p><p>The total body clearance of aripiprazole is 0.7 ml/min/kg, which is primarily hepatic.</p><p>Following a single oral dose of [14C]-labelled aripiprazole, approximately 27 % of the administered radioactivity was recovered in the urine and approximately 60 % in the faeces. Less than 1 % of unchanged aripiprazole was excreted in the urine and approximately 18 % was recovered unchanged in the faeces.</p><p><u>Paediatric population:</u></p><p>The pharmacokinetics of aripiprazole and dehydro-aripiprazole in paediatric patients 10 to 17 years of age were similar to those in adults after correcting for the differences in body weights.</p><p><u>Pharmacokinetics in special patient groups:</u></p><p>Elderly</p><p>There are no differences in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subjects, nor is there any detectable effect of age in a population pharmacokinetic analysis in schizophrenic patients.</p><p>Gender</p><p>There are no differences in the pharmacokinetics of aripiprazole between healthy male and female subjects nor is there any detectable effect of gender in a population pharmacokinetic analysis in schizophrenic patients.</p><p>Smoking</p><p>Population pharmacokinetic evaluation has revealed no evidence of clinically significant effects from smoking on the pharmacokinetics of aripiprazole.</p><p>Race Population pharmacokinetic evaluation showed no evidence of race-related differences on the pharmacokinetics of aripiprazole.</p><p>Renal impairment</p><p>The pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were found to be similar in patients with severe renal disease compared to young healthy subjects.</p><p>Hepatic impairment</p><p>A single-dose study in subjects with varying degrees of liver cirrhosis (Child-Pugh Classes A, B, and C) did not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study included only 3 patients with Class C liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.</p><p>Toxicologically significant effects were observed only at doses or exposures that were sufficiently in excess of the</p><p>maximum human dose or exposure, indicating that these effects were limited or of no relevance to clinical use. These included: dose-dependent adrenocortical toxicity (lipofuscin pigment accumulation and/or parenchymal cell loss) in rats after 104 weeks at 20 to 60 mg/kg/day (3 to 10 times the mean steady-state AUC at the maximum recommended human dose) and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at 60 mg/kg/day (10 times the mean steady-state AUC at the maximum recommended human dose).</p><p>&nbsp;The highest nontumorigenic exposure in female rats was 7 times the human exposure at the recommended dose.</p><p>An additional finding was cholelithiasis as a consequence of precipitation of sulphate conjugates of hydroxy metabolites of aripiprazole in the bile of monkeys after repeated oral dosing at 25 to 125 mg/kg/day (1 to 3 times the mean steadystate</p><p>AUC at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose</p><p>based on mg/m2).</p><p>However, the concentrations of the sulphate conjugates of hydroxy aripiprazole in human bile at the highest dose proposed, 30 mg per day, were no more than 6 % of the bile concentrations found in the monkeys in the 39-week study and are well below (6 %) their limits of in vitro solubility.</p><p>In repeat-dose studies in juvenile rats and dogs, the toxicity profile of aripiprazole was comparable to that observed in adult animals, and there was no evidence of neurotoxicity or adverse reactions on development.</p><p>Based on results of a full range of standard genotoxicity tests, aripiprazole was considered non-genotoxic. Aripiprazole did not impair fertility in reproductive toxicity studies. Developmental toxicity, including dose-dependent delayed fetal ossification and possible teratogenic effects, were observed in rats at doses resulting in sub therapeutic exposures (based on AUC) and in rabbits at doses resulting in exposures 3 and 11 times the mean steady-state AUC at the maximum recommended clinical dose. Maternal toxicity occurred at doses similar to those eliciting developmental toxicity.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate</p><p>Corn Starch</p><p>Microcrystalline cellulose</p><p>Hydroxypropyl cellulose</p><p>Magnesium stearate</p><p>Purified water</p><p>Ferric oxide Yellow &ndash; ( Zorta &nbsp;15mg)</p><p>Ferric oxide Red &ndash; ( Zorta &nbsp;10mg)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blisters in cartons of 30 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma Saudi,
Riyadh, Kingdome Saudi Arabia.
medical-ksa@mspharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dec,2020	
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>